EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
EyePoint Inc (EYPT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown some positive movement in the regular and post-market sessions, the technical indicators are neutral, and the financial performance shows significant revenue decline. Additionally, there are no strong positive catalysts or trading signals to support immediate action.
The MACD is below 0 and negatively contracting, the RSI is neutral at 39.029, and moving averages are converging. The stock is trading near its pivot level of 13.397, with resistance at 14.471 and support at 12.324. These indicators suggest no clear upward or downward trend.
Analyst rating remains Outperform, with confidence in the company's Phase 3 approach for Duravyu. The stock has a chance of gaining 1.78% in the next week based on historical patterns.
Revenue has dropped significantly (-90.82% YoY), and gross margin has declined (-72.73% YoY). The stock has a 40% chance of declining -4.56% in the next month. No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q3 2025, revenue dropped to $966,000 (-90.82% YoY). Net income improved to -$59.73M (+103.44% YoY), and EPS increased to -0.85 (+57.41% YoY). However, gross margin dropped to 25.36% (-72.73% YoY), indicating weak operational efficiency.
Mizuho analyst maintains an Outperform rating on EYPT, citing confidence in the company's Phase 3 Duravyu approach despite potential competition from Ocular Therapeutix's Axpaxli.
